Partnering with
MOGRIFY
Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, ex vivo cell therapy and in vivo reprogramming therapy to develop treatments for indications of high unmet clinical need. We are particularly interested in speaking with those with interest in hematological, immunological, ophthalmological as well as other disease areas where these modalities may be of interest. Mogrify is commercializing its technology via a combination of internal therapy development, co-development partnerships, and out-licensing of novel cell conversions applicable to non-core markets.
Our
PIPELINE
AREA | Sample Acquisition | Bioinformatics | In vitro PoC | In vivo PoC | IND | Clinical | Marketing |
---|---|---|---|---|---|---|---|
Ophthalmology | mogrify | mogrify | mogrify | partner | partner | ||
Immunology (& hematology) |
mogrify | mogrify | mogrify | mogrify | partner | partner | |
Collaborations (Pancreatic, Lung, Immune & Others) |
mogrify | mogrify | mogrify | partner | partner | partner | partner |
mogrify | Mogrify Progress | partner | Expect to Partner |

Upcoming
Events & Conferences
Smart cellular therapeutics of the future must be easily customizable, have intrinsic control systems to prevent toxicity, and be able to overcome rapidly evolving mechanisms preventing disease resolution; this conference aims to address these topics by convening global experts across a range of relevant disciplines.
In an industry as dynamic as the life science and healthcare sector, LSX World Congress brings the people who are tackling the biggest challenges in the industry today, and helps answer the question; where to next and how do we get there?
RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalized medicines, and treatment of genetic, infectious and chronic diseases.
The virtual BIO CEO & Investor Conference 2021 event, taking place February 16-18, will showcase the Biotechnology Innovation Organization’s (BIO) perspective on the new U.S. Congressional agenda, the record-setting pacing of biotech IPOs and the hottest clinical developments and industry catalysts.
The CAR-TCR Digital Summit Europe is the definitive platform for the European community to advance novel cell constructs, breach the solid tumor microenvironment, and deliver affordable CAR and TCR technologies to patients in need.
Systematically identify the epigenetically-predicted factors driving cell identity and cell maintenance for the development of scalable cell therapies.
The fifteenth annual BIO-Europe Spring® premier springtime partnering conference will be held March 22-25 in a fully digital format.
The theme of the 2021 ARVO Annual Meeting is the next revolution of clinically translating these discoveries to restore and preserve vision.
Join ASGCT for the field’s premier event, and take in the cutting edge science with leaders from academia, medicine, industry, advocacy, and more.
The first ELRIG meeting on Advances in Cell and Gene Therapies will be held on the 18th and 19th of May 2021 at the AstraZeneca R&D site in Gothenburg. This interactive 2-day conference will host world-leading scientists from academia and industry to discuss current and future perspectives of Cell and Gene Therapies.
Join the BIO International Convention 2021 to find innovative collaborations and partnerships.
The ISSCR Annual Meeting gathers the world’s leading scientists, clinicians, business leaders, ethicists, and educators from more than 65 countries. Together, we represent the full spectrum of stem cell science and regenerative medicine. Discovery, new business, careers, advocacy, and relationships start here.
We are proud to be sponsoring the Cambridge International Stem Cell Symposium in September 2021.